• Natera, Inc. reported past first-quarter 2026 results with revenue rising to US$696.64 million from US$501.83 million a year earlier, while net loss widened to US$85.09 million and basic loss per share from continuing operations increased to US$0.60.
• The company delivered record testing volumes, raised its 2026 revenue and gross margin guidance, yet reported a larger loss as operating expenses for clinical trials, new products and international expansion increased.
• We’ll now examine how Natera’s strong revenue growth but expanding losses in Q1 2026 affect its longer-term investment narrative.

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

Natera Investment Narrative Recap

To own Natera, you need to believe that growing adoption of its molecular tests in oncology, women’s health and organ health can ultimately outweigh today’s sizable losses. Q1 2026 reinforced that tension: record test volumes and higher revenue guidance support the growth story, while the wider net loss and 12.2% share price drop keep the path to profitability and spending discipline as the key near term catalyst and the biggest current risk, respectively.

The most relevant recent development here is Natera’s decision to raise its 2026 revenue outlook to US$2.74–US$2.82 billion and lift gross margin guidance to 64–66%. That step underlines management’s confidence that higher volumes and pricing can support better unit economics over time, even as Q1 showed how heavier R&D and commercial investments can still widen GAAP losses and fuel concern about when those investments begin to translate into sustained earnings improvements.

Yet while revenue is gaining ground, investors should be aware that...

Natera’s narrative projects $3.8 billion revenue and $129.1 million earnings by 2029. This requires 18.0% yearly revenue growth and a $337.3 million earnings increase from -$208.2 million today.

Uncover how Natera's forecasts yield a $259.11 fair value, a 30% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were assuming about US$3.7 billion of revenue by 2029 and still no profits, so Q1’s faster top line and deeper loss could easily shift how you judge whether high fixed costs and competitive pressure are manageable or a sign that Natera never reaches the scale those forecasts required.

Explore 5 other fair value estimates on Natera - why the stock might be worth just $206.81!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.